{"id":7529,"date":"2025-10-21T12:12:38","date_gmt":"2025-10-21T12:12:38","guid":{"rendered":"https:\/\/www.nfp-drugs.bg\/en\/?p=7529"},"modified":"2025-11-03T10:05:14","modified_gmt":"2025-11-03T10:05:14","slug":"2024-european-school-survey-project-on-alcohol-and-other-drugs-espad-report","status":"publish","type":"post","link":"https:\/\/www.nfp-drugs.bg\/en\/2024-european-school-survey-project-on-alcohol-and-other-drugs-espad-report\/","title":{"rendered":"2024 European School Survey Project on Alcohol and Other Drugs (ESPAD) report"},"content":{"rendered":"\n<p>The results of the&nbsp;<strong>2024 European School Survey Project on Alcohol and other Drugs (ESPAD)&nbsp;<\/strong>are released today in an extensive new&nbsp;<a rel=\"noreferrer noopener\" href=\"https:\/\/www.espad.org\/espad-report-2024\" target=\"_blank\">report analysing adolescent substance use behaviours across Europe<\/a>. The report \u2014 expanding on the&nbsp;<a href=\"https:\/\/www.euda.europa.eu\/publications\/data-factsheets\/espad-2024-key-findings_en\">key findings<\/a>&nbsp;published in May 2025 \u2014 portrays a generation \u2018in profound transition\u2019.&nbsp;<\/p>\n\n\n\n<p>The study, carried out in collaboration with the&nbsp;<strong>European Union Drugs Agency (EUDA)&nbsp;<\/strong>and coordinated by the&nbsp;<strong>Italian National Research Council (CNR)<\/strong>, is based on a 2024 survey in 37 European countries, including 25 EU Member States. This is the eighth data-collection wave conducted by the&nbsp;<strong>ESPAD<\/strong>&nbsp;project since 1995, and the first one carried out after the COVID-19 pandemic. A total of&nbsp;<strong>113 882 students&nbsp;<\/strong>(aged 15\u201316-years) participated in this latest survey round, responding to an anonymous questionnaire. This edition marks&nbsp;<strong>30 years<\/strong>&nbsp;of monitoring adolescent risky behaviours across Europe.<\/p>\n\n\n\n<p>Teenage drinking, smoking and cannabis use continue to decline but new behavioural and health risks are on the rise. The report flags growing concerns over increasing e-cigarette use, the non-medical use of pharmaceutical drugs and a sharp rise in social media use, online gaming and gambling among teenagers. These trends are most striking among girls, where long-standing gender gaps in substance use appear to be narrowing, or even reversing.<\/p>\n\n\n\n<p style=\"padding-top:15px\"><strong><a href=\"https:\/\/www.espad.org\/espad-report-2024\">ESPAD Report 2024<\/a><\/strong><\/p>\n\n\n\n<p style=\"padding-top:1px\"><strong><a href=\"https:\/\/www.euda.europa.eu\/publications\/data-factsheets\/espad-2024-key-findings_en\">Key findings from the ESPAD 2024<\/a><\/strong><\/p>\n\n\n\n<p><strong><a href=\"https:\/\/www.euda.europa.eu\/news\/2025\/latest-espad-report-calls-action-prevention-mental-health-and-digital-risks_en\">News release<\/a><\/strong><\/p>\n\n\n\n<p><strong><a href=\"https:\/\/data.espad.org\/\">ESPAD Data Portal<\/a><\/strong><\/p>\n\n\n\n<p><strong><a href=\"https:\/\/www.nfp-drugs.bg\/en\/2024-european-school-survey-project-on-alcohol-and-other-drugs-espad\/\">Comparison between national and European data <\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The results of the&nbsp;2024 European School Survey Project on Alcohol and other Drugs (ESPAD)&nbsp;are released today in an extensive new&nbsp;report analysing adolescent substance use behaviours across Europe. The report \u2014 expanding on the&nbsp;key findings&nbsp;published in May 2025 \u2014 portrays a generation \u2018in profound transition\u2019.&nbsp; The study, carried out in collaboration with the&nbsp;European Union Drugs Agency [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7531,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[],"_links":{"self":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/7529"}],"collection":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/comments?post=7529"}],"version-history":[{"count":4,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/7529\/revisions"}],"predecessor-version":[{"id":7547,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/posts\/7529\/revisions\/7547"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/media\/7531"}],"wp:attachment":[{"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/media?parent=7529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/categories?post=7529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nfp-drugs.bg\/en\/wp-json\/wp\/v2\/tags?post=7529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}